Biogen (BIIB) Retained Earnings (2009 - 2026)
Biogen (BIIB) posted quarterly Retained Earnings of $21.0 billion for Q2 2026, up 4.15% year-over-year from $20.1 billion in Q2 2025, and little changed quarter-over-quarter from $20.9 billion in Q1 2026.
Biogen (BIIB) Retained Earnings (2009 - 2026) Analysis & Trends
Biogen's Retained Earnings history runs 18 years deep, the most recent figure standing at $21.0 billion for Q2 2026.
- In Q2 2026, Retained Earnings rose 4.15% year-over-year to $21.0 billion; the TTM figure through Jun 2026 stood at $21.0 billion (up 4.15% YoY), while the FY2025 annual figure was $20.6 billion, up 6.71% from the prior year.
- Retained Earnings for Q2 2026 stood at $21.0 billion, roughly flat from $20.9 billion in the prior quarter.
- The five-year high for Retained Earnings was $21.0 billion in Q2 2026, with the low at -$172.8 million in Q2 2023.
- The 5-year median for Retained Earnings is $8.8 billion (2022), against an average of $9.8 billion.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings plunged 56.52% in 2023, then surged 13891.16% in 2025.
- Biogen's Retained Earnings stood at -$164.9 million in 2022, then jumped by 10789.87% to $17.6 billion in 2023, then climbed by 9.26% to $19.3 billion in 2024, then grew by 6.71% to $20.6 billion in 2025, then rose by 2.03% to $21.0 billion in 2026.
- Business Quant data shows BIIB's Retained Earnings at $21.0 billion in Q2 2026, $20.9 billion in Q1 2026, and $20.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 171.67 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -17.33 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 63.27 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 12.59 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -22.28 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 9.53 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 112.09 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 15.38 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 20.97 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.97 Bn |
| Mar 31, 2026 | 20.87 Bn |
| Dec 31, 2025 | 20.55 Bn |
| Sep 30, 2025 | 20.60 Bn |
| Jun 30, 2025 | 20.14 Bn |
| Mar 31, 2025 | 19.50 Bn |
| Dec 31, 2024 | 19.26 Bn |
| Sep 30, 2024 | 18.99 Bn |
| Jun 30, 2024 | -146.00 Mn |
| Mar 31, 2024 | -160.50 Mn |
| Dec 31, 2023 | 17.63 Bn |
| Sep 30, 2023 | -159.30 Mn |
| Jun 30, 2023 | -172.80 Mn |
| Mar 31, 2023 | -172.00 Mn |
| Dec 31, 2022 | -164.90 Mn |
| Sep 30, 2022 | -163.60 Mn |
| Jun 30, 2022 | -110.40 Mn |
| Mar 31, 2022 | -115.20 Mn |
| Dec 31, 2021 | -106.70 Mn |
| Sep 30, 2021 | -136.60 Mn |